Immunogenic compositions to treat and prevent microbial infections
Inventors
Daum, Luke T. • Fischer, Gerald W. • Sei, Clara J.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11866463-B2
Publication Date
2024-01-09
Expiration Date
Abstract
The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.
Core Innovation
The invention relates to a synthetic composite peptide antigen in which a plurality of different microbial epitopes are contained within a single peptide sequence. The composite peptide comprises a corona virus epitope and an influenza virus epitope, thereby combining epitopes from two different microbial infections in one contiguous sequence.
In another form, the invention provides a peptide that contains, as adjacent epitopes, a corona virus epitope, an influenza virus epitope, and a T cell stimulating epitope, all in one sequence. The composite format is described as immunogenic and intended to elicit immune responses relevant to both infections.
The problem being solved is the need for vaccines/therapeutics against microbial infections that provide immune recognition against influenza and coronaviruses, including broad, cross-strain protection by combining conserved epitopes. The background and description emphasize constructing composite peptide antigens that include multiple pathogen epitopes in one contiguous peptide sequence, optionally with a T cell stimulating epitope to support an immune response.
Claims Coverage
The partial claims content includes two independent claims. Across these, the inventive concepts focus on composite single-sequence peptides that present corona virus and influenza virus epitopes together, with an optional T cell stimulating epitope arranged as adjacent epitopes.
Single peptide with corona virus and influenza virus epitopes
A peptide containing a plurality of different microbial epitopes all as a single peptide sequence, wherein the plurality comprises a corona virus epitope and an influenza virus epitope.
Adjacent corona virus, influenza, and T cell stimulating epitopes in one sequence
A peptide containing as adjacent epitopes a corona virus epitope, an influenza virus epitope, and a T cell stimulating epitope as a single sequence.
The independent claims define composite vaccine peptide antigens as single contiguous sequences carrying multiple pathogen epitopes. One claim centers on combining a corona virus epitope and an influenza virus epitope within a single peptide sequence, and the second claim further specifies adjacency by adding a T cell stimulating epitope.
Stated Advantages
Broad, cross-strain protection against influenza and coronaviruses by combining conserved epitopes.
Induction of immunogenic antibody responses, including IgG responses and antibodies that bind live influenza viruses and neutralize H1N1/H3N2, as described.
Generation of monoclonal antibodies that bind a conserved Mycobacterium tuberculosis alpha-crystallin epitope and promote opsonophagocytic killing of mycobacteria, as described.
Saponin-derived adjuvants enhance immune responses across isotypes, as described.
Documented Applications
Vaccines/therapeutics against microbial infections, including synthetic composite antigen peptides intended to provide protection against influenza virus infection and coronavirus infection.
Immunogenic compositions that treat or prevent both influenza virus infection and corona virus infection, as described.
Mycobacterium tuberculosis immunization, generating hybridomas/monoclonal antibodies directed to a conserved MTB alpha-crystallin epitope and promoting opsonophagocytic killing, as described.
Interested in licensing this patent?